With Time, The Pathology of PD Spreads Throughout the Brain
|
|
- Susan Fitzgerald
- 6 years ago
- Views:
Transcription
1 With Time, The Pathology of PD Spreads Throughout the Brain Braak s staging of Parkinson s disease pathology dm co sn mc hc fc 1 Hubert H. Fernandez, MD, FAAN Professor of Medicine (Neurology) Cleveland Clinic Lerner College of Medicine Head, Section of Movement Disorders Center for Neurological Restoration Cleveland Clinic, Neurological Institute Cleveland, OH Cheryl H. Waters, MD, FRCPC Albert B. and Judith L. Glickman Professor Division of Movement Disorders Columbia University New York, NY co, coeruleus-subcoeruleus complex; dm, dorsal motor nucleus of the glossopharyngeal and vagal nerves; fc, first-order sensory association areas, premotor areas, as well as primary sensory and motor fields; hc, high-order sensory association areas and prefrontal fields; mc, anteromedial temporal mesocortex; sn, substantia nigra STAGES OF PD Braak H, et al. Cell Tissue Res. 2004;318: Parkinson s Disease (PD) Epidemiology Motor Features of PD Uncommon before age 50 years 1 Annual incidence (all ages): 8.6 to 19.0/100,000 2 Incidence increases dramatically with age: approximately 100/100,000 over age 70 years 3 Prevalence in individuals older than 65 years: approximately 1% 4 More common in men 5 Incidence of PD by age 90% Age 50 and under Greater than age Van Den Eeden SK, et al. Am J Epidemiol. 2003;157: Twelves D, et al. Mov Disord. 2003;18: von Campenhausen S, et al. Eur Neuropsychopharmacol. 2005;15: Fahn S. Ann N Y Acad Sci. 2003;991: Taylor KS, et al. J Neurol Neurosurg Psychiatry. 2007;78: % Cardinal features Rest tremor Rigidity Bradykinesia Postural instability Other motor features Masked face Shuffling gait Freezing Micrographia Dystonia Cramps 1
2 Autonomic Non-Motor Features of PD Constipation Hyperhidrosis Urinary dysfunction Sexual dysfunction Sialorrhea Psychiatric disorders Depression/Anxiety Apathy Fatigue Sleep disorders Insomnia REM behavior disorder Cognitive Dementia Psychosis Clinical Features that May Suggest a Diagnosis Other than PD Poor response to adequate dosages of levodopa Early onset of postural instability Axial more than appendicular rigidity Early dementia Supranuclear gaze palsy Profound autonomic dysfunction Significant limb dystonia prior to levodopa exposure Wenning GK, et al. J Neurol Neurosurg Psychiatry. 2000;68: Differential Diagnosis of PD Dopamine Transport Imaging (DaTscan ) Essential Vascular Drugs Tremor Progressive Supranuclear Palsy Multi- System Atrophy Toxins Secondary Idiopathic Parkinson s Disease Parkinson- Plus Other Normal Abnormal Encephalitis Other Alzheimer s Disease Lewy Body Disease Corticobasal Degeneration Neurodegenerative parkinsonism (ALL) Essential tremor Drug-induced parkinsonism Vascular parkinsonism Psychogenic Dopamine transport imaging differentiates between parkinsonian disorders with and without dopamine deficiency 2
3 Treatment Goals Can Exercise Slow PD Progression? Exercise Therapy Is Effective in Improving Activities of Daily Living Slowing disease progression Controlling symptoms Preserving quality of life Smith AD, et al. Exp Neurol. 2003;184: Tajiri N, et al. Brain Res. 2010;1310: Hackney ME, Earhart GM. Parkinsonism Relat Disord. 2009;15: Agents Recently or Currently Being Tested for Disease-Modifying Properties No Coenzyme Q10 Pramipexole Results Pending Creatine Inosine Isradipine Exercise Maybe Rasagiline Olanow CW, et al. N Engl J Med. 2009;361: Massachusetts Medical Society. Used with permission. Blood Brain Barrier Sites of Action of PD Drugs Substantia Nigra levodopa DA DDC COMT dopamine levodopa 3 OMD carbidopa amantadine COMT inhibitors: tolcapone entacapone MAO B inhibitors: selegiline rasagiline ACh Striatum GABA Dopamine agonists: bromocriptine pramipexole ropinirole rotigotine Anticholinergics: trihexyphenidyl benztropine Adapted from 3
4 Considerations in the Initial Management of PD Control of disability Favorable side-effect profile Optimal long-term strategy Cost Case Example 1 (Cont d) Examination reveals increased tone bilaterally, right greater than left; a rest tremor on the right; and bradykinesia in some tasks on the right. Right arm swing is depressed while walking. MRI normal, DaTscan-decreased uptake in the corpus striatum, especially on the left side. How would you treat this patient? Case Example 1 A 37-year-old male presents to your office with tremor of right hand for 4 to 5 years. He also has decreased manual dexterity on right and right foot cramping. He has a family history that is positive for essential tremor. His past medical history is unremarkable. Levodopa Clearly Beneficial as a Treatment of PD Change in total unified PD rating scale by dose of levodopa Fahn S, et al. N Engl J Med. 2004;351: Massachusetts Medical Society. Used with permission. 4
5 Levodopa Associated With Risk of Motor Complications Dyskinesia Peak dose End of dose Motor fluctuations End-of-dose wearing off Unpredictable on-off Yo-yo-ing 100 Adapted from: Schrag A, et al. Mov Disord. 1998;13: % BY 5 YEARS 100% BY 10 YEARS Time from Initiation of Therapy (years) Impulse Control Disorder (ICD) in PD Results from a multi-center study of 3000 patients ICDs were identified in 13.6% of PD patients overall: 17.1% of patients taking a dopamine agonist (DA) alone 6.9% of patients on levodopa, and not taking a DA Types of ICDs 5.7% compulsive buying 5.0% problem/pathologic gambling 4.3% binge eating disorder 3.5% compulsive sexual behavior Weintraub D, et al. Arch Neurol. 2010;67: Incidence rate for first occurrence (per 1000 person-years) Incidence (%) Occurrence of Dyskinesia: Initial Dopamine Agonist Therapy Dyskinesia Dystonia On/off Lees AJ, et al. Neurology. 2001;57(9): Levodopa Ropinirole Dyskinesia Levodopa Bromocriptine Dyskinesia before suppl levodopa Disabiling dyskinesia Incidence (%) Rascol O, et al. N Engl J Med. 2000;342(20): Incidence (%) Oertel WH, et al. Mov Disord. 2006;21(3): Parkinson Study Group. JAMA. 2000;284(15): MAO-B Inhibitors for Early PD Indications: monotherapy in early PD; add on to levodopa Available dosage: 1 mg tablet daily Benefits: mild symptomatic improvement; well tolerated Side effects: minimal; potential drug interactions Symptomatic treatment effect of rasagiline on total UPDRS at 6 months IMPROVEMENT Mean change from baseline in total UPDRS score Rasagiline 1 mg Rasagiline 2 mg Placebo P < P <.001 Parkinson Study Group. Arch Neurol. 2002;59(12): UPDRS: Unified Parkinson's Disease Rating Scale 5
6 Treatment-Emergent Adverse Events With Rasagiline Monotherapy* Percentage of Patients Placebo Rasagiline 1 mg/d Advanced Parkinson s Disease *Adverse-event incidence >5%; between-group differences not statistically significant Adapted from: Parkinson Study Group. Arch Neurol. 2002;59(12): AAN Practice Guidelines for Treatment of Early PD When symptomatic therapy is required: MAO-B inhibitors may be used. Either dopamine agonists or levodopa may be used when dopaminergic therapy is required. Levodopa provides better immediate symptomatic relief. Agonists have lower risk of motor complications, particularly dyskinesias. Agonists may carry a higher side effect profile. Miyasaki JM, et al. Neurology. 2002;58(1): Issues in Advanced PD Reduced quality of life 1 Functional impairment Higher risk of depression and cognitive impairment 2 Higher risk for comorbidities 2 Increased medical expenses 2 Caregiver burden and risk of early nursing home placement 2,3 1. Dodel RC, et al. Pharmacoeconomics. 2001;19: Parashos SA, et al. Mayo Clin Proc. 2002;77: Carter JH, et al. Mov Disord. 1998;13:
7 Problems in Advanced PD Causes of Falls Motor Neuropsychiatric Autonomic Postural instability Freezing Dyskinesia Hypotension Other neurological problems Environmental Motor Problems Fluctuations Dyskinesias Freezing of gait Falls Clinical Effect Schematic of Possible Changes in Clinical Effect in Patients as PD Progresses Diminishing Duration of Target Levodopa Response Early PD Dyskinesia Threshold Response Threshold Clinical Effect Moderate PD Dyskinesia Threshold Response Threshold Clinical Effect Advanced PD Dyskinesia Threshold Response Threshold Levodopa Time (h) Levodopa Time (h) Levodopa Time (h) Target Response Adapted with permission from: Obeso JA et al. In: Olanow CW, Obeso JA, eds. Beyond the Decade of the Brain. Vol 2. Dopamine agonists in early Parkinson s disease. Tunbridge Wells, UK: Wells Medical Ltd;1997:
8 Definition of Terms On state relatively good overall function and mobility corresponding to the medication working Off state relatively poor overall function and mobility corresponding to the medication not working Dyskinesias involuntary, nontremor movements Troublesome dyskinesias may be painful, impair balance, or are excessive to the point of causing impairment in coordination or general function Parkinson Study Group. Arch Neurol. 2005;62: Frequency of Levodopa-Induced Dyskinesia and Response Fluctuations by Age % Patients Age at Onset (years) (dyskinesias) (fluctuations) 40+ (dyskinesias) 40+ (fluctuations) Duration of Levodopa Treatment (years) Kostic V, et al. Neurology. 1991;41: n=25 in each group Treatment of Dyskinesia Peak dose or end of dose Treatment options include: Amantadine Clozapine (rarely used) Experimental therapy Deep Brain Stimulation (DBS) Mechanism: NMDA receptor antagonist, dopamine releasing agent Indications: Early PD, dyskinesias, fatigue Benefits: Mild symptomatic benefit, effective for dyskinesias Side effects: Leg swelling, livedo reticularis, neuropsychiatric, interacts with anticholinergics Amantadine Total dyskinesia Maximal dyskinesia UPDRS IVa dyskinesia UPDRS III motor off UPDRS III motor on Snow BJ, et al. Clin Neuropharmacol. 2000;23(2): Amantadine vs placebo for levodopa-induced dyskinesias Amantadine* Placebo* P value 22.0 (13.2) 29.0 (12.6) (2.6) 6.3 (2.2) (1.6) 4.3 (1.5) (14.8) 41.7 (13.0) (12.1) 23.4 (9.0) 0.44 NS *Mean score (SD) Wilcox signed-rank test 8
9 Case Example 2 A 65-year-old female with PD for 4 years is taking carbidopa/levodopa 25/100 QID. She is experiencing regular and predictable wearing off of the effect, 1½ hours prior to each dose. With this wearing off she gets painful foot dystonia and shortness of breath, as well as a return of her PD symptoms. How would you manage this patient? Examples of Other Off Symptoms Slowness of thinking Irritability Fatigue Drenching sweats Constipation Urinary urgency Abdominal bloating Pain Wearing Off Definition: Re-emergence of features of Parkinson s disease at end of dose May be motor or non-motor Case Example 2: Wearing Off Treatment Options Extended-release levodopa More frequent dosing of levodopa COMT inhibitors: entacapone or tolcapone Dopamine agonists MAO-B inhibitors Anticholinergics Botulinum toxin injection 9
10 Agents Commonly Used in the Management of PD Incidence of Non-Motor Symptoms of PD Levodopa COMT Inhibitors Tolcapone Entacapone MAO-B Inhibitors Selegiline Zydis selegiline Rasagiline Dopamine Agonists Pramipexole Ropinirole Bromocriptine Apomorphine Rotigotine Other Amantadine Anticholinergics ANS. dysfunction 80% Dementia 78% Sleep disorders * 66% Urogenital dysfunction 57-83% Gastrointestinal symptoms * 50-95% Fatigue 50% Orthostatic hypotension 50% Depression * 40-50% Pain 40-50% Impulse control disorders 7-14% *Identified as possible pre-motor symptoms ANS: autonomic nervous system Reichmann H, et al. Expert Opin. Pharmacother. 2009;10(5): Chaudhuri K, et al. Lancet Neurology. 2006;5: Non-Motor Features of PD Autonomic Constipation Hyperhidrosis Urinary dysfunction Sexual dysfunction Sialorrhea Psychiatric disorders Depression/anxiety Apathy Fatigue Sleep disorders Insomnia REM behavior disorder Cognitive Dementia Psychosis AAN Recommendations for Treatment of Non-motor Symptoms of PD Parameter Dementia Recommendation Donepezil should be considered Rivastigmine should be considered Evidence Level* Depression Amitriptyline may be considered C Insufficient evidence for other treatments U Fatigue Methylphenidate may be considered C Erectile Dysfunction Sildenafil citrate (50 mg) may be efficacious C Constipation Polyethylene glycol may be considered Insufficient evidence to support/refute the use of botulinum toxin Zesiewicz TA, et al. Neurology. 2010;74: Miyasaki JM, et al. Neurology. 2006;66: B B C U *Evidence level was based on the AAN s classification scheme : Off-label use 10
11 AAN Recommendations for Treatment of Non-motor Symptoms of PD (cont d) Parameter Orthostatic Hypotension Urinary Incontinence Anxiety REM Behavior Disorder (RBD) Insomnia Recommendation Insufficient evidence to support/refute treatment in PD Insufficient evidence to support/refute treatment in PD Insufficient evidence to support/refute the treatment of anxiety with levodopa Insufficient evidence to support/refute the treatment of RBD Clonazepam and melatonin are often used in the general population Insufficient evidence to support/refute the benefit of levodopa/carbidopa on objective sleep parameters that are not affected by motor status Insufficient evidence to support/refute the benefit of melatonin on the treatment of poor sleep quality Zesiewicz TA, et al. Neurology. 2010;74: Miyasaki JM, et al. Neurology. 2006;66: Evidence Level* *Evidence level was based on the AAN s classification scheme : Off-label use U U U U U U Case Example 3 A 75-year-old male retired physician comes to your office with PD and hallucinations. He is seeing deceased relatives in his house and accusing his wife of having an affair. His medications for PD include carbidopa/levodopa 25/100 QID. He continues to suffer from slowness and some disability. How would you manage this patient? Neuropsychiatric Management of Psychotic Symptoms Cognitive impairment and dementia Psychosis Compulsive disorders Depression Apathy Anxiety Rule out causes of mental status changes Infection Electrolyte imbalance Medications Modify PD regimen Reduce PD medications to minimum tolerable, yet effective dose Discontinue, if necessary Evaluate risk/benefit of atypical antipsychotic Priority of modification Anticholinergics Amantadine MAO-B inhibitors Dopamine agonists COMT inhibitors Levodopa/carbidopa 11
12 Therapy for Cognitive Impairment in PD Depression Cholinesterase inhibitors Memantine? Avoid anticholinergics Atypical neuroleptics Caregiver support CHANGE FROM BASELINE IN ADAS-cog SCORE P =.002 RIVASTIGMINE (n=329) PLACEBO (n=161) P < WEEK BASELINE DETERIORATION IMPROVEMENT Severe depression is unusual. Suicide is unusual. Weight loss, fatigue, insomnia can be due to PD or depression. Difficult to differentiate. Emre M, et al. New Engl J Med. 2004;351(24): Massachusetts Medical Society. Used with permission. Case Example 3 (Cont d) He is likely to have mild underlying dementia. He cannot lower his levodopa because he is quite impaired from the PD. His wife should get counseling. He should be treated with a cholinesterase inhibitor and an atypical antipsychotic (quetiapine and clozapine ONLY). Treatment of Depression in PD Very few studies have been conducted. Most antidepressants work, but very few randomized clinical trials exist. Caution with the side effects of antidepressants (low blood pressure, dry mouth, confusion and sedation with the tricyclics, and increased tremor and impotence with the SSRIs). 12
13 % decrease in the MADRS score Summary of PD Depression Double-Blind Studies Citalopram or desipramine vs placebo 1 Baseline Day 14 Day 30 Desipramine Placebo Citalopram Citalopram and desipramine both more effective than placebo, but significant shortterm effect (at 14 days) only with desipramine 1. Devos D, et al. Mov Disord. 2008;23(6): Menza M, et al. Neurology. 2009;72(10): HAM-D change Nortriptyline or paroxetine CR vs placebo 2 Weeks from baseline Placebo Paroxetine Nortriptyline Nortriptyline was superior to placebo; paroxetine was not Sleep Disorders Insomnia and sleep fragmentation Nightmares, hallucinations REM behavior disorder Sleep apnea Excess daytime sleepiness and sleep attacks Frequent urination PD immobility SAD-PD: Efficacy SAD-PD: Study of Antidepressants in PD Mean 12-Week in HAM-D Score (N=115) Comparison Effect 95% CI P-value Paroxetine vs Placebo -6.2 (-9.7, -2.7).0007 Venlafaxine vs Placebo -4.2 (-7.8, -0.6).02 Autonomic Dysfunction Constipation Urinary problems Sexual problems Orthostatic hypotension Sweating Pain Dysphagia Seborrhea Richard IH, et al. Neurology. 2012;78(16):
14 Orthostatic Hypotension Eliminate blood pressure medications. Try to stop PD medications (ie, dopamine agonists): Fludrocortisone Midodrine Pyridostigmine Domperidone (outside of US) Other Autonomic Problems Gastrointestinal (GI) Treat constipation No good treatments for gastroparesis Genitourinary (GU) Urinary anticholinergics may cause confusion and hallucinations Alpha adrenergic blocking agents may cause hypotension Gastrointestinal (GI) Problems Drooling Dysphagia Weight loss Gastroparesis Constipation Mild symptoms, no disability Does not yet need treatment When to Consider DBS Early Mild Moderate Advanced Symptoms with some disability May need treatment but not yet levodopa Worsening symptoms Need for levodopa ± adjunctive therapy TIME TO CONSIDER DBS Beginning of complications from disease and treatment Increasing disability despite therapy Complications of disease and treatment 14
15 Time Best Medical Therapy (BMT) vs DBS On without troublesome dyskinesia On with troublesome dyskinesia Patient Motor Diary Outcomes BMT change from baseline to 6 mos (n=134) DBS change from baseline to 6 mos (n=121) Mean difference between BMT vs DBS P value < <.001 Off <.001 Asleep Future Directions in PD Treatment Treat or restore function in advanced disease. Treat dyskinesia. Prevent development of motor complications. Treat nondopaminergic features. Neuroprotective treatments? Adapted from: Weaver FM, et al. JAMA. 2009;301: Adverse Events from DBS 40% of patients in study receiving DBS had a serious adverse event, including: Up to 3 months following DBS Fall (P =.02) Pain (P =.04) Confusional state (P <.001) Speech disorder (P =.004) Headache (P <.001) 4-6 months following DBS Dystonia (P =.02) Fall (P =.03) Question 1 Would dopamine agonists still be an option for Parkinson s patients with dementia and/or psychosis who have worsening motor symptoms? Weaver FM, et al. JAMA. 2009;301:
16 Question 2 Can deep brain stimulation (DBS) be considered in older patients? Question 4 In male patients with Parkinson s disease, if they suffer from postural hypotension is there an alternative to sildenafil for erectile dysfunction? Question 3 Are there effective treatments available for sialorrhea in patients with Parkinson s disease? Question 5 Why are only quetiapine and clozapine recommended for the treatment of psychosis in patients with Parkinson s disease? For these drugs, what are the starting doses? 16
17 Question 6 What are the best ways to assess and manage dysphagia in patients with Parkinson s disease? Question 8 What are the indications for botulinum toxins in Parkinson s disease? Question 7 Is there a maximum/ceiling dose of: Carbidopa/levodopa in patients with end-stage Parkinson s disease? Quetiapine in managing psychosis in Parkinson s disease? Question 9 Is the rotigotine patch a viable option for early Parkinson s disease? Is it an alternative to levodopa in those with advanced disease? 17
18 Question 10 How do you define a poor response to levodopa? Question 12 Does DBS necessitate changes in prior medical therapy? STN: subthalamic nucleus GPi: Globus Pallidus Pars Interna Question 11 Is there a hereditary component to Parkinson s disease? 18
10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationParkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported
More informationPre-Program Survey Please select the response that most closely matches your opinion:
BEFORE THE PROGRAM, PLEASE COMPLETE THE PRE-PROGRAM SURVEY ONLINE AT: www.cmecorner.com/12pdwc/pre If you are unable to complete the survey online, please print and complete this page before the program
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationParkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee
Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationAny interventions, where RCTs in PD are not available, are not included in the tables.
Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationParkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015
Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,
More informationPharmacological treatment of Parkinson's disease
Pharmacological treatment of Parkinson's disease Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon PD PROGRESSION DISABILITY instability
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More information10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.
Deep Brain Stimulation in the Treatment of Movement Disorders Disclosures None Eleanor K Orehek, M.D. Movement Disorders Specialist Noran Neurological Clinic 1 2 Objectives To provide an overview of deep
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationCE on SUNDAY Newark, NJ October 18, 2009
CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 10:30 AM 11:45 AM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Treating Parkinson s Disease: A Pharmacist s Overview
More informationParts of the motor circuits
MOVEMENT DISORDERS Parts of the motor circuits cortical centers: there are centers in all the cortical lobes subcortical centers: caudate nucleus putamen pallidum subthalamical nucleus (Luys) nucleus ruber
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More information14 : 4. D Nagaraja, Pramod Kumar Pal, N Karthik, Bangalore. Abstract:
14 : 4 Management of Parkinson s disease: What is new? Abstract: Parkinson s disease (PD) is a progressive disorder, which however can be treated satisfactorily with a judicial combination of medical and
More informationComprehensive Approach to DLB Management
Comprehensive Approach to DLB Management Bradley F. Boeve, MD Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Comprehensive Approach to DLB Management Disclosures
More informationASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease
ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease Parkinson s Disease Cardinal Signs: Resting tremor Rigidity Bradykinesia Postural instability Other Symptoms Dystonia Dysphagia Autonomic
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationDrugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE
ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE The Basal Ganglia Primary motor cortex Execution of movement
More informationCanadian Guidelines on Parkinson s Disease Executive Summary
Canadian Guidelines on Parkinson s Disease Executive Summary Re: Can J Neurol Sci. 2012;39: Suppl 4: S1-S30 The aim of the Canadian Guidelines on Parkinson s Disease is to enhance the care for all Canadians
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationParkinson s disease: diagnosis and current management
n DRUG REVIEW Parkinson s disease: diagnosis and current management Lucy Collins MPhil, Gemma Cummins MRCPI and Roger A Barker PhD, MRCP SPL Treatment for Parkinson s should be tailored to the needs of
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationDeep Brain Stimulation: Indications and Ethical Applications
Deep Brain Stimulation Overview Kara D. Beasley, DO, MBe, FACOS Boulder Neurosurgical and Spine Associates (303) 562-1372 Deep Brain Stimulation: Indications and Ethical Applications Instrument of Change
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals
More informationThe Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo
The Latest Research in Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo OR.. Rethinking Parkinson s Disease Lawrence Elmer, MD, PhD Professor, Dept. of Neurology
More informationFOUNDATION OF UNDERSTANDING PARKINSON S DISEASE
FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationParkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center
Parkinsons Disease update Sindhu R Srivatsal MD MPH Virginia Mason Medical Center PARKINSONISM Vs PARKINSON S Parkinsonism Bradykinesia: slowness of movements (essential feature) PLUS one of Tremor: resting
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationIssues for Patient Discussion
onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More information2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor
Parkinson s Disease History of Parkinson s It s much more than tremor Laura Dixon, DNP, MPA, APRN, FNP-BC University of Louisville Department of Neurology Movement Disorders Division Parkinson s Disease
More informationDepression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS
Depression & Anxiety One set of important protectors from depression is friends and family as much as you can, keep yourself active and engaged with others. Exercise, particularly while outside, may help.
More informationMAXIMIZING FUNCTION IN PARKINSON S DISEASE
1 MAXIMIZING FUNCTION IN PARKINSON S DISEASE September 13, 2016 End Falls This Falls Conference Jan Goldstein Elman One Step Ahead Mobility Toronto, Ontario Outline An overview of Parkinson s disease (PD):
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationUpdate on the Treatment of Parkinson s Disease. Neurotherapeutics for Rehab Professionals November 6 th, 2015
Brent Bluett, DO Dr. Brent Bluett completed medical school at Touro Unviersity Nevada College of Osteopathic Medicine, neurology residency at the University of Texas Southwestern at Austin, and a Movement
More informationParkinson s disease and primary care
Neurology 427 Parkinson s disease and primary care The publication of the 2006 NICE guidelines for Parkinson s disease may seem to have taken much of the management of patients with Parkinson s disease
More informationParkinson s disease. Quick reference guide. Issue date: June Diagnosis and management in primary and secondary care
Quick reference guide Issue date: June 2006 Parkinson s disease Diagnosis and management in primary and secondary care Developed by the National Collaborating Centre for Chronic Conditions Contents Contents
More informationParkinson's Disease KP Update
Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have
More informationTHE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE
THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE J O N AT H A N S Q U I R E S, M D, F R C P C C L I N I C A L I N S T R U C T O R, UBC F AC U L T Y O F M E D I C I N E P AC I F I C P AR K I N S
More informationNon-Motor Symptoms of Parkinson s Disease
Non-Motor Symptoms of Parkinson s Disease Samantha Holden, MD University of Colorado Movement Disorders MOTOR SYMPTOMS Rigidity Bradykinesia Tremor Gait Imbalance NON-MOTOR SYMPTOMS Dementia Urinary frequency
More informationObjectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures
12:45 1:30 pm PD or not PD? Distinguishing Parkinson s Disease From Other Parkinsonian and Tremor Syndromes SPEAKER Jennifer G. Goldman, MD, MS Presenter Disclosure Information The following relationships
More informationMovement Disorders. Eric Kraus, MD! Neurology!
Movement Disorders Eric Kraus, MD! Neurology! Classify Bradykinesia! Tic! Myoclonus! Tremor! Dystonia! Athetosis! Chorea! Ballismus! Case 1 This 64 year-old female has had progression of a tremor over
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationThe Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia
Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationDeep Brain Stimulation: Patient selection
Deep Brain Stimulation: Patient selection Halim Fadil, MD Movement Disorders Neurologist Kane Hall Barry Neurology Bedford/Keller, TX 1991: Thalamic (Vim) DBS for tremor Benabid AL, et al. Lancet. 1991;337(8738):403-406.
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationEvidence compendium. Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease
Evidence compendium Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease CONTENTS Introduction... 4 Index of study summaries... 6 Parkinson s disease
More informationPsychiatric aspects of Parkinson s disease an update
Psychiatric aspects of Parkinson s disease an update Dr Chris Collins 027 2787593 chris.collins@cdhb.health.nz Disclosures: none Non-motor aspects physical Sensory anosmia, visual symptoms Speech and
More informationEMERGING TREATMENTS FOR PARKINSON S DISEASE
EMERGING TREATMENTS FOR PARKINSON S DISEASE Katerina Markopoulou, MD, PhD Director Neurodegenerative Diseases Program Department of Neurology NorthShore University HealthSystem Clinical Assistant Professor
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationThe PD You Don t See: Cognitive and Non-motor Symptoms
The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Assistant Professor of Neurology and Psychiatry University of Colorado Denver Goals 1) What are the most common non-motor
More informationNICE guideline Published: 19 July 2017 nice.org.uk/guidance/ng71
Parkinson s disease in adults NICE guideline Published: 19 July 2017 nice.org.uk/guidance/ng71 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More information